BIOGAMI Teaming Profiles
This page is designed to help facilitate connections between prospective proposers, which ARPA-H anticipates will be necessary to achieve the goals of the BIOmolecular Grammar for protein Aggregation Modulation and Intervention (BIOGAMI) program. Prospective performers are encouraged (but not required) to form teams with varied technical expertise to submit a proposal.
If either you or your organization are interested in teaming, please create a profile via the ARPA-H Solutions Portal linked below. Your details will then be added to this page, which is publicly available.
Please note that by publishing the teaming profiles list, ARPA-H is not endorsing, sponsoring, or otherwise evaluating the qualifications of the individuals or organizations included here. Submissions to the teaming profiles list are reviewed and updated periodically.
BIOGAMI Teaming Profiles
To narrow the results in the Teaming Profiles List, please use the input below to filter results based on your search term. The list will filter as you type.
| A | AA | AAA | AAA | AAA | AAA | AAA |
| Jyotika Varshney | Verisim Life Inc. | jo.varshney@verisimlife.com | San Francisco, CA | VeriSIM Life focuses on the design and prediction of protein behavior in human biology using hybrid AI and mechanistic modeling. Our BIOiSIM® platform integrates machine learning with molecular, biophysical, and physiology-based simulations to decode how sequence and environmental perturbations influence protein conformations, aggregation propensity, and downstream organ- and patient-level outcomes, enabling early intervention, therapeutic design, and risk reduction. | We seek partners with deep expertise in intrinsically disordered proteins, protein misfolding/aggregation biology, and experimental assay systems. Ideal collaborators generate mechanistic or high-content molecular data that can be integrated into our translational AI framework to connect early protein-level interventions with downstream in vivo exposure, safety, and functional outcomes relevant to disease prevention. | TA2: Modulate IDPs to detect and control protein folding |
| George (Bill) Jackson | Base Pair Biotechnologies, Inc. | bill.jackson@basepairbio.com | Houston, TX | Founded in 2012, BasePair is the leading provider of custom *aptamer* discovery services. In addition to our target-agnostic, patented platform for *multiplexed* aptamer discovery, we have a keen interest in applying aptamers to neurological disorders. Using BasePair aptamers, we and our customers have developed sensors and assays for literally hundreds of unique protein and peptide targets. Aptamers have a potential role in BIOGAMI for both diagnostics and as folding "chaperones". | Looking to partner as a subcontractor to any group developing biosensors or therapeutic interventions under this initiative. In addition to de novo aptamer discovery, we can develop prototype sensors with a variety of transduction mechanisms. We also provide custom cell culture services and biophysical characterizations. Finally, BasePair supports multiple customers in therapeutic aptamer development and delivery technologies including BBB-crossing aptamers and nose-to-brain delivery. | TA2: Modulate IDPs to detect and control protein folding, TA1: Establish the molecular grammar of IDRs |
| Varun Gadkari | University of Minnesota | vgadkari@umn.edu | Minneapolis, MN | We develop native ion mobility-mass spectrometry which can effectively make measurements of protein misfolding and oligomerization in the gas phase. This approach is tolerant of complex mixtures (e.g., multiple oligomeric states in solution) and can be used to quantitatively analyze individual components of this mixture. Once protein oligomer complexes are in the mass spectrometer, we can use gas-phase energy deposition to analyze the stability, structural properties of disordered oligomers. | We are looking for experts in solution-phase methods to characterize IDP systems who can validate our measurements and provide other complementary measurements. We would also need partners who can design and synthesize drugs to test. Our methods are ideal for high throughput screening, but we are not molecule makers. Lastly we would need partners with access to tissue samples to translate our work, and experts in AI/computation to meet the priorities of the call. | TA2: Modulate IDPs to detect and control protein folding, TA1: Establish the molecular grammar of IDRs |
| Andrew Stern | Brigham and Women's Hospital | astern@bwh.harvard.edu | Boston, MA | I am a clinical neurologist and basic scientist analyzing the state of amyloid-forming proteins as they exist in the human brain. I have AI collaborations and we are interested in the BIOGAMI application. | Structural biologists interested in amyloid formation and developing methods for AI model design. | TA2: Modulate IDPs to detect and control protein folding, TA1: Establish the molecular grammar of IDRs |
| Chirag Patel | Harvard Medical School | Chirag_Patel@hms.harvard.edu | Boston, MA | Artificial intelligence, exposomics, genomics | AD expertise | TA1: Establish the molecular grammar of IDRs |
| Vijaya Kolachalama | Boston University | vkola@bu.edu | Boston, MA | Research and development | Experts in various fields | TA1: Establish the molecular grammar of IDRs, TA2: Modulate IDPs to detect and control protein folding |
| Theodosia Bartashevitch | Amylnac | theodosiabartashevitch@gmail.com | Culver City, CA | Early amyloid structure prediction | Experimental validation, TA2 | TA1: Establish the molecular grammar of IDRs |
| Steven Santos | Danaher | ssantos04@dhdiagnostics.com | Washington, DC | Neurodegenerative Diagnostics | - | TA2: Modulate IDPs to detect and control protein folding |
| Xuan Wang | Virginia Tech | xuanw@vt.edu | Blacksburg, VA | Our research focuses on AI models for biological and healthcare data, with an emphasis on training efficient foundation and small foundation models for multimodal inputs. We develop methods for optimizing neural architectures, agent frameworks, and training strategies that capture biological grammar and structure–function relationships, enabling robust, interpretable models for complex biological systems. | We are seeking teams with strong expertise in protein science, biophysics, or experimental biology who are interested in integrating advanced AI methods. In particular, we aim to collaborate with partners developing data, assays, or models for intrinsically disordered proteins and aggregation, where our AI and agentic training methods can support modeling, interpretation, and early-stage detection. | TA1: Establish the molecular grammar of IDRs |
| Zoya Gluzman-Poltorak | Forta Bio | Zoya@forta.bio | San Diego and San Francisco, CA | Forta Bio is developing a novel class of targeted, “naked” oligonucleotide therapeutics called ODC™ molecules (Oligonucleotide-Dependent Cytotoxicity) and FortaAI™ (FortaGuideAI™), an integrated AI engine for designing and optimizing these therapeutics. This platform enables a new modality of programmable, cell-selective DNA/RNA therapeutics that combine targeted delivery, intracellular activation, and immune modulation in a single, synthetically simple molecule. | We are looking for codeveloping of targeted CNS therapeutics for neurodegenerative diseases using our ODC novel technology that provides targeted brain delivery via BBB crossing aptamers and immunomodulatory component. The ideal partner will have identified a relevant target and proven MOA in vivo that can be combined with our modality. | TA2: Modulate IDPs to detect and control protein folding |
| June Lee, MD, PhD | NSMS | Dr.JuneLee@nsmsusa.org | Bethesda, MD | NSMS is a clinical powerhouse driving TA2 and TA3 via autonomous AI-driven pharmacology. Our team utilizes self-optimizing ML models for autonomous PK/PD prediction and predictive allometric scaling of protein modulators. We operate GLP-compliant facilities for IND-enabling studies, integrating autonomous bioanalytical pipelines with CSF microdialysis to validate BBB penetration. We ensure "grammar" edits achieve human-ready bioavailability through AI-steered translation. | We seek TA1 (Modeling) and TA2 (Discovery) partners with novel "grammar-based" modalities (ASOs, PROTACs, small molecules) needing a clinical transition engine. NSMS provides the pharmacological rigor and FDA/IND regulatory strategy to bridge the gap to TA3 implementation. We seek collaborators with high-potency candidates who require expert solutions for BBB transport, metabolic stability, and human dose-prediction to ensure successful clinical translation. | TA2: Modulate IDPs to detect and control protein folding, TA1: Establish the molecular grammar of IDRs |
| Avi Samelson | University of California, Los Angeles | asamelson@ucla.edu | Los Angeles, CA | My lab uses high-throughput methods in iPSC-derived neurons to understand the basis for IDP aggregation and behavior. | I am looking for people who have AI and MD experience as well as mass spectrometry-based structural biology | TA1: Establish the molecular grammar of IDRs, TA2: Modulate IDPs to detect and control protein folding |
| Priyanka Joshi | Georgetown University Medical Center | priyanka.joshi@georgetown.edu | Washington DC, DC | The Laboratory of Biomolecular Homeostasis and Resilience investigates protein folding mechanisms in aging and neurodegenerative disease using mass spectrometry-based structural proteomics, AI-driven approaches, and multi-scale biology. We specialize in metabolite-protein interactions affecting proteostasis, environmental triggers of protein aggregation, physical exposures-induced protein conformational changes and developing predictive models for aggregation propensity in crowded environments. | We generate high-throughput environmental perturbation data and structural proteomics readouts. We seek AI/ML partners for discovering environment-to-aggregation grammar at scale and computational teams for testing grammar-based predictions through rational design. | TA2: Modulate IDPs to detect and control protein folding, TA1: Establish the molecular grammar of IDRs |
| Farshid Roumi | Parthian | froumi@parthiannrg.com | Los Angeles and San Jose, CA | We are a spinoff from Caltech (mechanical engineering and electrical.computer enginneering) 1- developed a low cost yet high sensitivity magnetic based sensing technology. 2- Mathematical model for phase transformation (reversible and irreversible shape changing) in advanced materials (eg. Austenite/martensite transformation in bacteriophage). 3- mechanical geometry (as Dr. Marsden work at Caltech) which helps predict the folding mechanism based on a robust mathematical model | We can do the mathematical model and simulations. We are looking for a numerical biology group to partner with. | TA2: Modulate IDPs to detect and control protein folding, TA1: Establish the molecular grammar of IDRs |
| Peter Koulen | UMKC | koulenp@umkc.edu | Kansas City, MO | Development of neuroprotective therapeutics | molecular modeling expertise | TA1: Establish the molecular grammar of IDRs, TA2: Modulate IDPs to detect and control protein folding |
| Daojing Wang | Newomics Inc. | wang@newomics.com | Berkeley, CA | Develop and commercialize advanced mass spectrometry technologies, to identify, quantify, and characterize biomolecules and biomolecular interactions in vitro and in cellular and organismal systems, with high throughput and high sensitivity. | Open to teaming possibilities. | TA1: Establish the molecular grammar of IDRs, TA2: Modulate IDPs to detect and control protein folding |
| Hakima Ibaroudene | Southwest Research Institute | hibaroudene@swri.org | San Antonio, TX | Southwest Research Institute (SwRI) is an independent, nonprofit research organization. For BIOGAMI, SwRI will lead computational work to uncover the rules of intrinsically disordered proteins and use data from partners to check and improve the models. | SwRI seeks partners with expertise in intrinsically disordered proteins, experimental validation, protein design, high-dimensional cellular data, and translational research. Ideal collaborators complement SwRI’s AI modeling by providing data, testing predictions, and connecting findings to disease-relevant systems. | TA1: Establish the molecular grammar of IDRs, TA2: Modulate IDPs to detect and control protein folding |
| Krishna Mallela | University of Colorado Anschutz Medical Campus | krishna.mallela@cuanschutz.edu | Aurora, CO | Biophysics, Structural Biology, Protein Structure-Function, AI/ML methods | Access to large data sets | TA1: Establish the molecular grammar of IDRs, TA2: Modulate IDPs to detect and control protein folding |
| Eran Seger | Protai | eran@protai.bio | Tel Aviv, Israel | Protai is focusing on protein complex modeling by combining structural proteomics and AI based protein folding algorithms. We use that to accurately predict the protein complex structure and different conformations, that can be highly relevant for the understanding of formation of aggregation. | Neurodegenerative focused companies, holding good experimental models of these deceases, and looking for a strong AI and structural physics partner. | TA2: Modulate IDPs to detect and control protein folding, TA1: Establish the molecular grammar of IDRs |
| Han Xiao | RICE UNIVERSITY | han.xiao@rice.edu | Houston, TX | Our research program integrates three pillars to combat neurodegenerative diseases. First, a precision imaging platform uses genetically encoded "molecular rotors" to detect early-stage protein misfolding in live cells (NCB, 2026, 22, 97). Second, an ML system forecasts how mutations and environments impact protein aggregation. Third, an ML- based design system tailored for the targeted degradation of proteins containing specific sequences. | We are looking for teaming partners who possess established disease models or are interested in translating novel technology | TA1: Establish the molecular grammar of IDRs, TA2: Modulate IDPs to detect and control protein folding |
| Patricia Clark | University of Notre Dame | pclark1@nd.edu | South Bend, IN | We develop novel experimental systems in the test tube and cell to assess protein folding, the dimensions of disordered protein conformational ensembles, and protein aggregation. For example, work from our lab was instrumental to resolving the “SAXS versus FRET debate” regarding the extent of collapse in disordered conformational ensembles, prior to protein folding (e.g., Riback et al. 2017, 2018, 2019). | We seek to work closely with computational scientists to develop and test predictive models. | TA1: Establish the molecular grammar of IDRs, TA2: Modulate IDPs to detect and control protein folding |
| Maria Rodriguez Martinez | Yale University | maria.rodriguezmartinez@yale.edu | New Haven, CT | The Department of Biomedical Informatics and Data Science (BIDS) at Yale School of Medicine is an interdisciplinary department advancing biomedical research through data science, machine learning, and computational modeling. BIDS integrates AI, statistics, computer science, and biomedical sciences, with strengths in computational biology, genomics and proteomics, clinical informatics, and AI-driven modeling, closely connected to Yale’s clinical and experimental research programs. | We are seeking teaming partners with complementary expertise in protein biophysics and experimental characterization of intrinsically disordered and aggregation-prone proteins, including advanced structural, biophysical, and cellular assays. Ideal partners bring capabilities in early detection of protein misfolding, novel therapeutic or modulation strategies, and/or high-throughput experimental validation. | TA1: Establish the molecular grammar of IDRs, TA2: Modulate IDPs to detect and control protein folding |
| Matt Sigmund | SIA/LBG | Msigmund@lathambiopharm.com | Elkridge, MD | Sia/LBG provides full-spectrum support for federal funding, specializing in proposal development and post-award execution. Our subject matter experts in digital health bring deep domain knowledge in areas like health IT, AI-driven diagnostics, and data interoperability. We craft compliant, compelling proposals tailored to funder priorities and guide post-award reporting, stakeholder engagement, and program delivery to ensure lasting success. | SIA/LBG is seeking to partner with organizations developing innovative, breakthrough technologies with the potential to satisfy program requirements and that are interested in engaging an experienced partner to enhance proposal development and ensure disciplined, compliant post-award program execution. | TA2: Modulate IDPs to detect and control protein folding, TA1: Establish the molecular grammar of IDRs |
| Josef Grey | Grey Theorem | Advisory@Greytheorem.com | Research Triangle Park, NC | Market Research, Economics, Life Sciences Advisory - focus in RNA Biochemistry and multivariable mathematical modeling and forecasting | Market Intelligence, Market Research, Science technical advisory | TA2: Modulate IDPs to detect and control protein folding, TA1: Establish the molecular grammar of IDRs |
| Abigail Cember | Rhino Federated Computing | abby@rhinofcp.com | Boston, MA | Federated computing architectures enable organizations or teams of organizations to analyze large, multi-source data (‘federated analytics’) or to train machine learning models (‘federated learning’) on such data without compromising the privacy of individual datasets therein, or, if needed, of the model or calculation itself. Our R&D efforts currently focus on features related to agentic AI, retrieval-augmented generation (RAG), and (bio)chemical structure-function prediction. | We seek to support teams comprised of multiple industry partners -- or mixes of academic and industry partners -- by providing the digital infrastructure that allows for model training without giving rise to concerns over the IP attached to individual compounds or molecules. | TA1: Establish the molecular grammar of IDRs, TA2: Modulate IDPs to detect and control protein folding |
| Nataraj Pagadala | LigronBio Inc | npagadala@ligronbio.com | San Diego, CA | Targeted Molecular Glue Conjugation at β Sheet-Linked Degrons in Intrinsically Disordered Proteins/Regions (IDP/IDRs) to Reverse Protein Misfolding and Aggregation | We are seeking teaming partners with strong capabilities in experimental biology, neurodegeneration, protein biophysics, structural biology, and in‑vitro/in‑vivo validation. Ideal collaborators bring complementary wet‑lab expertise, scalable assays, disease‑relevant models, and a shared commitment to advancing transformative therapeutics. | TA1: Establish the molecular grammar of IDRs, TA2: Modulate IDPs to detect and control protein folding |
| Yuyu Song | MGH | ysong13@mgh.harvard.edu | Boston, MA | Proteostasis in neurodegeneration. Structure-function analysis of IDP in axonal degeneration. | Technician advances and methods to study IDP dynamic folding in vivo. | TA2: Modulate IDPs to detect and control protein folding, TA1: Establish the molecular grammar of IDRs |
| Adam Hott | CFD Research Corp | adam.hott@cfd-research.com | Huntsville, AL | CFD Research specializes in engineering simulations and biomedical innovations. We have advanced organ-on-a-chip platforms, PBPK/QSAR/Molecular dynamics modeling, microfluidic diagnostics, and bioinformatics. Our capabilities span high-throughput cell sorting, point-of-care testing, multi-omic sensing, and AI-driven informatics. Our labs support molecular biology, microfabrication, virology, and cell culture. | We are actively looking for both university and industry partners to round out our team. We are especially interested in organizations with strong protein structural modeling capabilities. | TA1: Establish the molecular grammar of IDRs, TA2: Modulate IDPs to detect and control protein folding |
| Shanna Ratnesar-Shumate | The Johns Hopkins Applied Physics Laboratory | shanna.ratnesar-shumate@jhuapl.edu | Laurel, MD | modeling/prediction of protein folding and binding | develop novel therapeutics | TA1: Establish the molecular grammar of IDRs, TA2: Modulate IDPs to detect and control protein folding |
| Luke Berchowitz | Columbia University Medical Center | leb2210@cumc.columbia.edu | New York City, NY | My research focuses on the evolution and function of intrinsically disordered regions (IDRs) in germline and meiotic contexts. I study how rapidly evolving IDRs encode conserved biological functions, including regulated protein assembly, translational control, and genome defense. Using yeast genetics, cross-species rescue, and sequence–function dissection, my work defines biophysical and evolutionary constraints that allow IDRs to remain flexible yet functional across deep evolutionary time. | We are seeking teaming partners with deep expertise in structural biology, particularly NMR spectroscopy, to define structure, dynamics, and assembly states of challenging protein systems. Ideal partners bring experience with disordered and partially ordered proteins, protein–protein interactions, and solution-state methods that complement genetics and cell biology, enabling rigorous structure–function analysis across physiological conditions. | TA1: Establish the molecular grammar of IDRs, TA2: Modulate IDPs to detect and control protein folding |
| Damon Wang | Nucyrna Therapeutics | damon.wang@nucyrnatx.com | Boston, MA | Nucyrna Therapeutics is developing next-generation antibody–oligonucleotide conjugates (AOCs) to bypass the blood–brain barrier, enable single- or dual-RNA targeting, and treat neurodegenerative diseases. | We are seeking partners with expertise in detecting intrinsically disordered regions (IDRs) in disease models, including Huntington’s disease and additional disorders. | TA2: Modulate IDPs to detect and control protein folding, TA1: Establish the molecular grammar of IDRs |
| Kenneth Bowden | The Johns Hopkins University Applied Physics Lab | kenneth.bowden@jhuapl.edu | Laurel, MD | JHU APL’s RED Biology team focuses on disease/health monitoring, biothreat detection/mitigation, biomanufacturing, and operational biology. We develop high-throughput experimental assays and analytics/ML pipelines to characterize biomolecular interactions and enable early detection. These strengths translate to BIOGAMI TA1 assay/model development for IDR “grammar” and TA2 indicator/sensor concepts and validation support. | We are seeking teaming partners with in vitro and/or in vivo mammalian model capabilities (e.g., engineered cell lines, primary cells, organoids, or animal models) to enable perturbation/validation of IDR/IDP behavior, folding/aggregation phenotypes, and biomarker readouts, including access to relevant disease models and wet-lab validation capacity. | TA1: Establish the molecular grammar of IDRs, TA2: Modulate IDPs to detect and control protein folding |
| Allison Walker | Vanderbilt University | allison.s.walker@vanderbilt.edu | Nashville, TN | My lab develops AI and other computational methods to predict protein function, engineer proteins, and for drug discovery. A collaborating lab at my institution can provide in vitro characterization of aggregation dynamics. | We would like to team up with partners with expertise in in vivo studies and animal models for diseases relevant to this funding opportunity. | TA1: Establish the molecular grammar of IDRs, TA2: Modulate IDPs to detect and control protein folding |
| Advait Holkar | Praio | aholkar@praio.co | Berkeley, CA | Praio focuses on the creation and utilization of Artificial Protocells based on biomolecular condensation in vitro using diverse macromolecules for bespoke applications. We have developed high throughput methods for characterizing and quantifying biomolecular condensates and are producing Condensate Screening Panels for the frictionless testing for different use cases. | We are looking for experts in the computational modelling of IDPs with whom we can collaborate to experimentally refine folding and condensation models. We are also looking for TA2 experts who can enable intracellular delivery of the designed macromolecules to evaluate their theraputic efficacy. | TA2: Modulate IDPs to detect and control protein folding, TA1: Establish the molecular grammar of IDRs |
| Michael Craig | Kings College London | Michael.c.craig@kcl.ac.uk | London | Creation of mRNA encoded antibodies and development of lipid nanoparticles to treat disease. | Funding | TA2: Modulate IDPs to detect and control protein folding, TA2: Modulate IDPs to detect and control protein folding |
| Shady Saad | Stanford University | shady.saad@gmail.com | Stanford, CA | We are creating a translational platform to treat aggregation-driven diseases by converting our recent mechanistic discoveries (Saad et al., Cell, 2025) and extensive proof-of-concept data into therapeutics. By blocking early aggregation without altering protein expression, our approach aims to enable disease-modifying cures. POC data demonstrate aggregate clearance across Huntingtin, TDP-43, Aβ42, IAPP, and FUS. | We seek partners to accelerate therapeutic modularity and delivery. While peptides have validated our POC and may represent a final therapeutic modality, we also aim to expand into small molecules, RNA, and aptamers. Partners with expertise in chemical screening, directed evolution, viral delivery, and neurodegenerative mouse models would strongly enhance program progression. We also seek collaborators in AI-based binder prediction and molecular docking to complement and scale our platform. | TA2: Modulate IDPs to detect and control protein folding, TA1: Establish the molecular grammar of IDRs |
| Rohit Pappu | Washington University in St. Louis | pappu@wustl.edu | St. Louis, MO | We are leaders in the field of IDRs. Our organization has played a central role in establishing that IDRs are defined by molecular grammars and in demonstrating that grammars help determine sub-cellular localization preferences of proteins with IDRs, the functions of IDRs, the compositional specificities of condensates, and emergent material as well as electrochemical properties of condensates. Our center for biomolecular condensates covers a range of technologies, techniques, and tools. | We might be interested in tie-ups or collaborations that we do not cover in our current portfolio or are not represented in our panel of tie-ups that we have already established. | TA1: Establish the molecular grammar of IDRs, TA2: Modulate IDPs to detect and control protein folding |
| Andrew Spielberg | Carnegie Mellon University | aespielberg@gmail.com | Pittsburgh, PA | Physical Simulation for Design, Machine Learning and Optimization-Based Inverse Design, Additive Manufacturing, Sim-To-Real Methods, Robotics | Experience in grammar induction + search; looking for people who can bring more domain expertise to complement algorithmic expertise | TA1: Establish the molecular grammar of IDRs, TA2: Modulate IDPs to detect and control protein folding |
| Jun Park | UCLA | jop@ucla.edu | Los Angeles, CA | Brain Metabolomics, Proteomics, and Fluxomics | Industry partners and protein folding experts | TA2: Modulate IDPs to detect and control protein folding, TA1: Establish the molecular grammar of IDRs |
| Christopher Barden | Treventis Corporation | cbarden@treventis.com | Toronto Ontario Canada | Treventis has an end-to-end discovery workflow associated with doing small molecule drug design against IDPs. We have a patented in silico approach for identifying potential pharmacophores relevant to stabilizing regions of IDP and blocking dimerization and further oligomerization. We have a program partnered with Takeda Pharmaceuticals to block the misfolding of tau and have further programs in development against beta-amyloid, TDP-43, and mutant p53 but are broadly interest in IDP drug design. | We would welcome the opportunity to partner with like-minded organizations that possess interesting HTS assays or biophysical assays looking at IDPs. Treventis has a library of novel compounds that are derived from our platform and thus enriched in anti-misfolding potential. Our molecules could be valuable tools for identifying IDP binding sites and showing anti-misfolding IDPs. We are particularly interested in partners who have models for rare and non-neuro protein misfolding diseases. | TA2: Modulate IDPs to detect and control protein folding, TA1: Establish the molecular grammar of IDRs |
| Jared Kushner | Columbia University | jsk2018@cumc.columbia.edu | n/a, NY | We specialize in animal models of heart disease. Whether through the genetic design or viral delivery of transgenes, silencers or gene editing enzymes, we routinely analyze changes in heart rhythm as well as multiple parameters of systolic and diastolic function in the heart and blood vessels in vivo and ex vivo, from the whole-organ to the level of single cells. | We will test novel binders of amyloidogenic proteins in vitro and in animal models of cardiomyopathy for any of several different amyloid disease models. | TA2: Modulate IDPs to detect and control protein folding |
| Joseph Rayman | Columbia University | jbr2114@columbia.edu | New York, NY | We are developing small molecules that selectively inhibit formation of tau oligomers, a major pathogenic species of tau that is implicated in Alzheimer’s disease and other tauopathies. | We are interested in testing our compounds in human-derived cell and tissue models. We would also like to incorporate AI-based tools for SAR studies and lead optimization. | TA2: Modulate IDPs to detect and control protein folding, TA1: Establish the molecular grammar of IDRs |
| Natalie Ma | Deep Origin | nma@deeporigin.com | South San Francisco, CA | Deep Origin builds models that provide confidence that molecules will be safe and effective in clinic, throughout drug discovery and development. Deep Origin has developed a protein dynamics engine that can model de novo structure and dynamics, which has previously been used to model intrinsically-disordered proteins. Combined with Deep Origin's proprietary safety + efficacy models for drug design and development, Deep Origin can address in silico/platform components of TA1 and TA2. | - High-throughput wetlab experiment methods to characterize IDPs, ideally with experience across multiple IDP classes. - Biological expertise on validity/therapeutic utility of targeting different IDP proteins. - Drug development expertise, particularly ex vivo, in vivo, and clinical efficacy assessment. | TA1: Establish the molecular grammar of IDRs, TA2: Modulate IDPs to detect and control protein folding |
| Bryan Ngo | Post Translational Medicines | bryan@ptmedicines.com | San Francisco and New York City, CA | Post Translational Medicines focuses on discovering and drugging structurally distinct proteoforms that arise from dysfunctional cellular states. Our tehcnology enables proteome-wide, in-cellulo identification of druggable protein states—often invisible to conventional structural biology and AI approaches—to develop restorative precision medicines for cancer, aging, and age-related diseases. | Post Translational Medicines seeks academic and industry partners with complementary strengths in biology, chemistry, computation, and translational science who share an interest in uncovering and targeting post-translationally regulated proteoforms. Ideal partners bring deep disease expertise, enabling technologies, or development capabilities, and value collaborative discovery to translate novel protein states into transformative medicines. | TA1: Establish the molecular grammar of IDRs, TA2: Modulate IDPs to detect and control protein folding |
| Sarah Sipe | Parallel Squared Technology Institute | rkrasner@parallelsq.org | Watertown, MA, USA, MA | Single cell and bulk proteomics analysis of human brain tissue samples from AD and non-AD patients using LC-MS. | Expertise in protein structure AI model builders and experts in developing therapeutic interventions useful to add to screening process. | TA2: Modulate IDPs to detect and control protein folding |
| Stephen Haggarty | Massachusetts General Hospital | shaggarty@mgh.harvard.edu | Boston, MA | We are utlizing patient-derived stem cell models to characerize proteinopathies, with a major foucs on tau as an intrinsically disordered protein. We have developed unique biochemical methods to purify endogenous oligomers and insoluble tau proteoforms along with machine learning-based methods to screen for novel chemical probes of tau proteostasis, including bifunctional PROTACs and AUTOTACs that selectively target and degrade misfolded tau species. | We are looking for complementary expertise in structural biology, machine learning, and work with post-mortem human brain material, along with additional expertise in biophysical assays. | TA2: Modulate IDPs to detect and control protein folding, TA1: Establish the molecular grammar of IDRs |
| Tyona Pike | Foresight Initiatives | ty.pike@casemanagementpatientadvocacy.org | Cookeville, TN | Foresight Initiatives is a WOSB focused on case management and patient advocacy for individuals with genetic, rare, and chronic conditions. We design and run patient‑centered support pathways, collect structured real‑world and patient‑reported data, and translate complex scientific advances into usable information for patients, caregivers, and clinicians. | We seek BIOGAMI teams leading TA1/TA2 experimental and computational work that want a partner to maximize patient and end‑user impact. We offer value in indication and cohort definition, patient and caregiver recruitment, outcomes and usability input, navigation of real‑world care settings, and commercialization/adoption strategy that aligns tools and therapeutics with actual patient needs. | TA2: Modulate IDPs to detect and control protein folding |
| Yasamin Jodat | Lagomics | yasamin@lagomics.com | San Francisco, CA | Lagomics is developing a scalable, cell-free measurement platform to generate high-quality protein interaction data for grounding and validating biological foundation models. Using barcoded, library-on-library assays, we test thousands of proteins against diverse targets in pooled experiments, producing multiplexed functional readouts of binding, specificity, and off-target effects to close the gap between structure, function, and model performance. | Lagomics is seeking teaming partners with protein foundation models or PLMs that require experimentally grounded training or evaluation data. Ideal partners include groups doing structure-to-function prediction, generative protein design, or conformational modeling, as well as wet-lab teams able to perform secondary functional assays (e.g. signaling, activity, toxicity) to benchmark and validate model predictions using our interaction datasets. | TA1: Establish the molecular grammar of IDRs, TA2: Modulate IDPs to detect and control protein folding |
| Parijat Bhatnagar | Tribe Research | xparijat@gmail.com | Belmont, CA, USA, CA | Cell engineering and manufacturing technologies | We are looking for SME with insight into disease pathology related to intrinsically disordered proteins. | TA2: Modulate IDPs to detect and control protein folding, TA1: Establish the molecular grammar of IDRs |
| Reuben Hogan | UCSF | Reuben.hogan@ucsf.edu | San Francisco, CA | My PhD work involved using glycoproteomics to reliably determine the composition of glycans that are attached to proteins. It is known that N-Glycosylation, where a glycan is attached to the Nitrogen atom of an asparagine, is used to facilitate binding of nascent proteins to chaperone proteins in the ER to ensure appropriate disulfide arrangements. My work has helped contribute to reliable analysis of glycoproteins, glycosites, and glycans. | I am a single individual with the skills to operate a mass spectrometer, prepare samples, design methods, perform data analysis, and communicate the results of research. I am looking for a team that would have access to instrumentation and lab space. I bring additional knowledge of other players in the field who can assist with mass spectrometry instrumentation, corresponding glycomic analysis, detailed glycan structure analysis, and more. | TA1: Establish the molecular grammar of IDRs, TA2: Modulate IDPs to detect and control protein folding |
| Donghoon Lee | Omphalos Lifesciences Inc | donghoon.lee@omphaloslifesci.com | Dallas, TX | We build large-scale mechanistic whole-cell models to understand biology as an integrated system. We excel at exploring large combinatorial scenario spaces that are difficult or impractical to test experimentally, enabling discovery of single and combinatorial therapeutic targets, de-risking candidate selection, and guiding experimental and preclinical development. Synthetic functions and intervention strategies are designed and tested in silico. | We seek partners who value biological rigor and close collaboration. Teams with strong experimental expertise in protein folding, IDR biology, and disease-relevant cell, organoid, or in vivo models are ideal. We value collaborators who want to pair large-scale in silico exploration with focused, high-quality experiments to accelerate translation. | TA2: Modulate IDPs to detect and control protein folding, TA1: Establish the molecular grammar of IDRs |
| Judith Steen | Harvard Medical School | judith.steen@childrens.harvard.edu | Boston, MA | Protein chemistry, large data analysis, drug screening, | medicinal chemists and therapeutic antibody developers | TA2: Modulate IDPs to detect and control protein folding, TA1: Establish the molecular grammar of IDRs |
| Eugenia Clerico | Northwestern University | eugenia.clerico@northwestern.edu | Evanston, IL | The Proteostasis Consortium focuses on the fundamental biology of protein folding and misfolding as drivers of neurodegenerative and other protein misfolding diseases. We combine mechanistic discovery with in vitro, cellular, and organismal models, predictive modeling, and pharmacological strategies to modulate protein folding, enabling new approaches for intervention and translational development. | We seek teams with advanced AI/ML expertise to develop predictive algorithms for protein folding and misfolding. Key capabilities include training data acquisition and processing, data quality control, handling missing data, defining training/test sets, and updating models as new data become available. These skills will integrate with our experimental platforms to accelerate discovery of modulators and early detection tools. | TA2: Modulate IDPs to detect and control protein folding, TA1: Establish the molecular grammar of IDRs |
| Jeremy Linsley | Operant BioPharma | jeremylinsley@operant.bio | San Francisco, CA | Operant BioPharma uses AI-guided optogenetics to decode protein misfolding diseases. Our platform: (1) optogenetically controls IDR aggregation (tau, α-synuclein, TDP-43); (2) tracks proteostasis pathways in live cells via optical pulse labeling; (3) applies inverse biological process deep learning for drug discovery; (4)designs precision protein binders. We generate dynamic single-cell datasets revealing early disease mechanisms invisible to static approaches. | Seeking: (1) CryoEM for structural validation of IDR states and designed binders; (2) Non-neurodegenerative disease models (diabetes/amylin, cancer/p53, amyloidosis) to show platform breadth; (3) Academic IDR biology expertise. We bring commercial therapeutic development, AI-guided discovery, optogenetic aggregation control, live-cell proteostasis tracking, computational protein design, medicinal chemistry, and dynamic phenotyping capabilities. | TA2: Modulate IDPs to detect and control protein folding, TA1: Establish the molecular grammar of IDRs |
| Layla Starr | Synapticure | layla@synapticure.com | Philadelphia, PA, PA | Synapticure is a virtual 50-state specialty medical group that is the most accessible provider of ND care. We serve thousands of diverse ND patients, with many in disadvantaged communities by ADI. We collect longitudinal standardized data from our highly engaged patients under a single clinic structure, providing a valuable dataset existing primarily outside any collection today. We have run studies (e.g., 100+ ALS patient EAP with blood collection), collected samples for research, and more. | Synapticure’s core focus is clinical operations and services related to patient care. We believe we can reduce time from discovery to market by years through our offerings. We offer study capabilities, and sample collection, including patient-derived cell lines under IRB. We seek partners who can support machine learning, low-to-high throughput screening, imaging, target validation and IP development. We are eager to test drug repurposing in our population and support others developing novel IP. | TA1: Establish the molecular grammar of IDRs, TA2: Modulate IDPs to detect and control protein folding |
| Ramgopal Mettu | Tulane University | rmettu@tulane.edu | New Orleans, LA | Our group focuses on the modeling of adaptive immune response with a focus on antigen structure and conformational stability. We have shown that antigenic structure is a critical additional piece of the puzzle of predicting CD4+ T cell response, and believe it is of interest for therapeutic design. In particular we believe that for BIOGAMI, our computational methods can be the first step in a successful pipeline to identify and address immunological mechanisms initiated by disordered proteins. | Our team has strength in modeling immune response, so ideal partners would be interested in modeling aggregation with respect to downstream immune signals. We also seek partners that work on experimentally characterizing structure of specific antigens that we can work with to conduct downstream computational analyses. | TA1: Establish the molecular grammar of IDRs, TA1: Establish the molecular grammar of IDRs |
| Michael Dzuricky | Donaldson Company Inc | mdzuricky@gmail.com | Durham, NC | Utilizing IDPs for purification problems | Partners that have high throughput screening capabilities | TA1: Establish the molecular grammar of IDRs, TA2: Modulate IDPs to detect and control protein folding |
| Morkos Henen | University of Colorado, School of Medicine, USA | morkos.henen@cuanschutz.edu | Denver, CO | We focus on deciphering how post-translational modifications of intrinsically disordered regions in the dynein machinery alter their functions. This understanding paves the way for insights into neurodegenerative diseases associated with mutations in this machinery. | We would like to have a partner to translate our in vitro research into cell-based assays | TA1: Establish the molecular grammar of IDRs, TA1: Establish the molecular grammar of IDRs |
| Brian Kraemer | University of Washington | kraemerb@uw.edu | Seattle, WA | My group focuses on protein aggregates in neurodegeneration. Justin English will be the primary representative of our team (University of Washington Institute for Protein Design). My role is more focused on translation of IPD findings into therapeutic ideas in model systems. I would like to attend to represent the translational interests of our group while Dr. English will represent the computational and protein design interests. Dr. ENglish will submit our lightning talk proposal. | I defer to Drs. Baker and English on our groups teaming needs. I am a more junior member of the team. | TA1: Establish the molecular grammar of IDRs, TA2: Modulate IDPs to detect and control protein folding |
| Justin English | Institute for Protein Design, UW | jge1@uw.edu | Seattle, WA | The Institute for Protein Design, founded by Nobel Laureate David Baker, is the world's leading academic center in the computational modeling, design, and application of de novo proteins to advance human health. Over the past 10 years we have produced the leading models for predicting how proteins will interact with one another and their environment to resolve the processes of biology at the molecular level. Our work has resulted in the formation of dozens of companies addressing human disease. | General interest in synergistic methods to our existing approaches to resolve protein grammar. | TA1: Establish the molecular grammar of IDRs, TA2: Modulate IDPs to detect and control protein folding |